Clinical Trial Update: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating an anti-CD38 antibody-drug conjugate for relapsed or refractory multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-CD38 antibody-drug conjugate

Snippet

Sponsor: Zhejiang ACEA Pharmaceutical Co. Ltd. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING